NEURONETICS, INC.

(STIM)
  Report
Delayed Nasdaq  -  05/20 04:00:00 pm EDT
2.400 USD   -4.00%
05/17New Peer-Reviewed Data Continue to Further Best Practices with NeuroStar® Advanced Therapy
GL
05/17New Peer-Reviewed Data Continue to Further Best Practices with NeuroStar® Advanced Therapy
AQ
05/12NEURONETICS, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-Q)
AQ
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Health Care Stocks Return to Positive Ground This Afternoon

01/10/2022 | 03:46pm EDT


© MT Newswires 2022
Stocks mentioned in the article
ChangeLast1st jan.
AMICUS THERAPEUTICS, INC. 4.58% 7.76 Delayed Quote.-32.81%
BIOCRYST PHARMACEUTICALS, INC. 0.78% 9.1 Delayed Quote.-34.30%
GINKGO BIOWORKS HOLDINGS, INC. 3.57% 2.61 Delayed Quote.-68.59%
NASDAQ COMP. -0.30% 11354.62 Real-time Quote.-27.42%
NEURONETICS, INC. -4.00% 2.4 Delayed Quote.-46.19%
SELECTA BIOSCIENCES, INC. 2.76% 0.7958 Delayed Quote.-75.59%
All news about NEURONETICS, INC.
05/17New Peer-Reviewed Data Continue to Further Best Practices with NeuroStar® Advanced Ther..
GL
05/17New Peer-Reviewed Data Continue to Further Best Practices with NeuroStar® Advanced Ther..
AQ
05/12NEURONETICS, INC. Management's Discussion and Analysis of Financial Condition and Resu..
AQ
05/12TRANSCRIPT : Neuronetics, Inc., Q1 2022 Earnings Call, May 12, 2022
CI
05/12NEURONETICS : Q1 Earnings Snapshot
AQ
05/12Earnings Flash (STIM) NEURONETICS Posts Q1 Revenue $14.2M, vs. Street Est of $13.5M
MT
05/12Neuronetics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022
CI
05/12NEURONETICS, INC. : Regulation FD Disclosure (form 8-K)
AQ
05/12Neuronetics Reports First Quarter 2022 Financial and Operating Results
AQ
05/12Neuronetics, Inc. Provides Earning Guidance for the Second Quarter and Full Year of 202..
CI
More news
Analyst Recommendations on NEURONETICS, INC.
More recommendations
Financials (USD)
Sales 2022 61,1 M - -
Net income 2022 -44,2 M - -
Net Debt 2022 - - -
P/E ratio 2022 -1,46x
Yield 2022 -
Capitalization 64,3 M 64,3 M -
Capi. / Sales 2022 1,05x
Capi. / Sales 2023 0,88x
Nbr of Employees 187
Free-Float 96,9%
Chart NEURONETICS, INC.
Duration : Period :
Neuronetics, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends NEURONETICS, INC.
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 5
Last Close Price 2,40 $
Average target price 9,67 $
Spread / Average Target 303%
EPS Revisions
Managers and Directors
Keith J. Sullivan President, Chief Executive Officer & Director
Stephen Furlong Chief Financial Officer & Vice President-Finance
Robert A. Cascella Chairman
Cory Anderson VP-Clinical Affairs & Medical Operations
W. Andrew Macan Secretary, Chief Compliance Officer & Senior VP
Sector and Competitors
1st jan.Capi. (M$)
NEURONETICS, INC.-46.19%64
THERMO FISHER SCIENTIFIC-17.46%217 320
DANAHER CORPORATION-23.47%180 262
INTUITIVE SURGICAL, INC.-39.03%78 637
SIEMENS HEALTHINEERS AG-16.99%64 649
EDWARDS LIFESCIENCES CORPORATION-27.19%58 644